Volume 23, Number 12—December 2017
CME ACTIVITY - Research
Group B Streptococcus Infections Caused by Improper Sourcing and Handling of Fish for Raw Consumption, Singapore, 2015–2016
In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate. For CME questions, see page XXX.
Release date: November 15, 2017; Expiration date: November 15, 2018
Upon completion of this activity, participants will be able to:
• Evaluate clinical and epidemiological findings of a human group B Streptococcus outbreak in Singapore, based on a microbial study of raw fish and human samples
• Determine the pathogenic potential of fish and human samples after a human group B Streptococcus outbreak in Singapore, based on a microbial study of these samples
• Assess the public health implications of a human group B Streptococcus outbreak in Singapore, based on a microbial study of raw fish and human samples.
Thomas J. Gryczan, MS, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Thomas J. Gryczan, MS, has disclosed no relevant financial relationships.
Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed the following relevant financial relationships: owns stock, stock options, or bonds from Alnylam; Biogen; Pfizer.
Disclosures: Man Ling Chau, BSc; Swaine L. Chen, MD, PhD; Min Yap, BSc; Sri Harminda Pahm Hartantyo, PhD; Paul King Tiong Chiew, DVM, MVPM; Charlene Judith Fernandez, BS, DVM, MPH, CPH; Wai Kwan Wong, BSc; Rockey Kwonghung Fong, BVSc; Wei Ling Tan, BSc; Brian Zi Yan Tan, PhD; Youming Ng, BSc; Kyaw Thu Aung, MBBS, MSc, PGDip; Kurosh S. Mehershahi, PhD; Christopher Goh, MSc; Joanne Su Lin Kang, PhD; Timothy Barkham, MBBS, MSc, FRCPath; Adeline Oi Kheng Leong, MSc; Ramona Alikiiteaga Gutiérrez, DVM, PhD; and Lee Ching Ng, PhD, have disclosed no relevant financial relationships.>
- Page created: November 15, 2017
- Page last updated: November 15, 2017
- Page last reviewed: November 15, 2017
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)